The impact of face-mask mandates on all-cause mortality in Switzerland: a quasi-experimental study.


Journal

European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966

Informations de publication

Date de publication:
03 10 2022
Historique:
pubmed: 11 9 2022
medline: 5 10 2022
entrez: 10 9 2022
Statut: ppublish

Résumé

Whereas there is strong evidence that wearing a face mask is effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evidence on the impact of mandating the wearing of face masks on deaths from coronavirus disease 2019 (COVID-19) and all-cause mortality is more sparse and likely to vary by context. Focusing on a quasi-experimental setting in Switzerland, we aimed to determine (i) the effect of face-mask mandates for indoor public spaces on all-cause mortality; and (ii) how the effect has varied over time, and by age and sex. Our analysis exploited the fact that between July and October 2020, nine cantons in Switzerland extended a face-mask mandate at different time points from being restricted to public transportation only to applying to all public indoor places. We used both a Difference-in-Differences approach with fixed-effects for canton and week and an event-study approach. In our main Difference-in-Differences model, the face-mask mandate was associated with a 0.3% reduction in all-cause mortality [95% confidence interval (CI): -3.4% to 2.7%; P = 0.818]. This null effect was confirmed in the event-study approach and a variety of robustness checks. Combining the face-mask mandate with social distancing rules led to an estimated 5.1% (95% CI: -7.9% to -2.4%; P = 0.001) reduction in all-cause mortality. Mandating face-mask use in public indoor spaces in Switzerland in mid-to-late 2020 does not appear to have resulted in large reductions in all-cause mortality in the short term. There is some suggestion that combining face-mask mandates with social distancing rules reduced all-cause mortality.

Sections du résumé

BACKGROUND
Whereas there is strong evidence that wearing a face mask is effective in reducing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evidence on the impact of mandating the wearing of face masks on deaths from coronavirus disease 2019 (COVID-19) and all-cause mortality is more sparse and likely to vary by context. Focusing on a quasi-experimental setting in Switzerland, we aimed to determine (i) the effect of face-mask mandates for indoor public spaces on all-cause mortality; and (ii) how the effect has varied over time, and by age and sex.
METHODS
Our analysis exploited the fact that between July and October 2020, nine cantons in Switzerland extended a face-mask mandate at different time points from being restricted to public transportation only to applying to all public indoor places. We used both a Difference-in-Differences approach with fixed-effects for canton and week and an event-study approach.
RESULTS
In our main Difference-in-Differences model, the face-mask mandate was associated with a 0.3% reduction in all-cause mortality [95% confidence interval (CI): -3.4% to 2.7%; P = 0.818]. This null effect was confirmed in the event-study approach and a variety of robustness checks. Combining the face-mask mandate with social distancing rules led to an estimated 5.1% (95% CI: -7.9% to -2.4%; P = 0.001) reduction in all-cause mortality.
CONCLUSIONS
Mandating face-mask use in public indoor spaces in Switzerland in mid-to-late 2020 does not appear to have resulted in large reductions in all-cause mortality in the short term. There is some suggestion that combining face-mask mandates with social distancing rules reduced all-cause mortality.

Identifiants

pubmed: 36087339
pii: 6695430
doi: 10.1093/eurpub/ckac123
pmc: PMC9527954
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

818-824

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association.

Références

PLoS Negl Trop Dis. 2015 Jul 16;9(7):e0003846
pubmed: 26181387
Science. 2021 May 20;:
pubmed: 34016743
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200264
pubmed: 34053267
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32293-32301
pubmed: 33273115
BMJ. 2015 Apr 09;350:h694
pubmed: 25858901
J Econom. 2021 Jan;220(1):23-62
pubmed: 33100476
Health Aff (Millwood). 2020 Aug;39(8):1419-1425
pubmed: 32543923
Science. 2021 Feb 19;371(6531):
pubmed: 33323424
Science. 2022 Jan 14;375(6577):eabi9069
pubmed: 34855513
PLoS One. 2020 Aug 14;15(8):e0237691
pubmed: 32797067
Am J Trop Med Hyg. 2020 Dec;103(6):2400-2411
pubmed: 33124541
J Reg Sci. 2021 Sep;61(4):799-825
pubmed: 34230689
Nature. 2020 Aug;584(7820):262-267
pubmed: 32512578
J Health Econ. 2021 Jul;78:102475
pubmed: 34157513
BMJ. 2021 Nov 17;375:e068302
pubmed: 34789505
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33431650
Ann Intern Med. 2021 Mar;174(3):335-343
pubmed: 33205991
Int J Infect Dis. 2020 May;94:116-118
pubmed: 32320809

Auteurs

Giacomo De Giorgi (G)

Institute of Economics and Econometrics, Geneva School of Economics and Management, University of Geneva, Geneva 4, Switzerland.
BREAD, Bureau for Research and Economic Analysis of Development, E Providence, RI, USA.
CEPR, Centre for Economic Policy Research, London, UK.
IPA, Innovations for Poverty Action, Washington, DC, USA.

Pascal Geldsetzer (P)

Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, USA.
Chan Zuckerberg Biohub, San Francisco, CA, USA.

Felix Michalik (F)

Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.

M Maddalena Speziali (MM)

Institute of Economics and Econometrics, Geneva School of Economics and Management, University of Geneva, Geneva 4, Switzerland.
University Magna Graecia of Catanzaro, Catanzaro, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH